{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:33:52Z","timestamp":1777131232266,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.fjurol.2026.103094","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:31:52Z","timestamp":1772559112000},"page":"103094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term persistence of intradetrusor botulinum toxin in patients with multiple sclerosis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6497-6017","authenticated-orcid":false,"given":"Florian","family":"Patigny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6616-7688","authenticated-orcid":false,"given":"H\u00e9l\u00e9na","family":"Cassol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6608-7118","authenticated-orcid":false,"given":"B\u00e9rang\u00e8re","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Kaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-8422","authenticated-orcid":false,"given":"David","family":"Waltregny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Keppenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.fjurol.2026.103094_bib0105","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103094_bib0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","article-title":"Epidemiology of multiple sclerosis","volume":"172","author":"Leray","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1016\/j.fjurol.2026.103094_bib0115","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103094_bib0120","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"International Francophone Neuro-Urological expert study group (GENULF). The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"De S\u00e8ze","year":"2007","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103094_bib0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","article-title":"Management of neurogenic bladder in patients with multiple sclerosis","volume":"13","author":"Ph\u00e9","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"1\u20132","key":"10.1016\/j.fjurol.2026.103094_bib0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5489\/cuaj.4058","article-title":"Evaluation of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines","volume":"11","author":"Aharony","year":"2017","journal-title":"CUAJ"},{"key":"10.1016\/j.fjurol.2026.103094_bib0135","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botunilum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?\u00a0Preliminary results","author":"Schurch","year":"2000","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2026.103094_bib0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/toxins16100423","article-title":"Real-world use of intradetrusor botulinum toxin injections: a population-based study from France","volume":"16","author":"Ruffion","year":"2024","journal-title":"Toxins"},{"key":"10.1016\/j.fjurol.2026.103094_bib0145","series-title":"The AUA\/SUFU Guideline on adult neurogenic lower urinary tract dysfunction","author":"Gousse","year":"2021"},{"key":"10.1016\/j.fjurol.2026.103094_bib0150","series-title":"EAU Guidelines on Neuro-Urology","author":"Gajewski","year":"2024"},{"key":"10.1016\/j.fjurol.2026.103094_bib0155","series-title":"Injections intrad\u00e9trusoriennes de toxine botulique dans les HVN. Fiche pratique","year":"2025"},{"issue":"Suppl. 3","key":"10.1016\/j.fjurol.2026.103094_bib0160","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.12968\/bjon.2022.31.Sup3.S1","article-title":"Expert opinion consensus document: management of bladder dysfunction in people with multiple sclerosis","volume":"31","author":"Thomas","year":"2022","journal-title":"Br J Nurs"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103094_bib0165","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/nau.25427","article-title":"How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity","volume":"43","author":"Mailho","year":"2024","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103094_bib0170","first-page":"196","article-title":"Long-term results of botulinum toxin A injections in neurogenic detrusor overactivity: a multicenter study of 416 patients","volume":"26","author":"Chartier-Kastler","year":"2016","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103094_bib0175","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103094_bib0180","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103094_bib0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.purol.2019.02.003","article-title":"Efficacit\u00e9 au long terme de la toxine botulique dans l\u2019hyperactivit\u00e9 de vessie chez les patients atteints de scl\u00e9rose en plaques","volume":"29","author":"Gabay","year":"2019","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103094_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/luts.12297","article-title":"How long does the effect of botulinum toxin in neurogenic patients last? An analysis of the subset of \u201cgood responders\u201d","volume":"12","author":"Dominique","year":"2020","journal-title":"Low Urin Tract Symptoms."},{"issue":"1","key":"10.1016\/j.fjurol.2026.103094_bib0195","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1002\/bco2.479","article-title":"Long-term follow-up of intradetrusor botulinum toxin utilisation: a comparison of patients with multiple sclerosis and idiopathic overactive bladder","volume":"6","author":"Chui","year":"2025","journal-title":"BJUI Compass"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103094_bib0200","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1177\/13524585231174580","volume":"29","author":"Delaval","year":"2023","journal-title":"Mult Scler"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:35:00Z","timestamp":1777127700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2950393026000252"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103094","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term persistence of intradetrusor botulinum toxin in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103094"}}